Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Completed

A Study of Imatinib and Nilotinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase

NCT02272777

Conditions
Bone Marrow Diseases, Chronic Disease, Disease Attributes, +16 more
Locations
  • Novartis Investigative Site Guangzhou, Guangdong, China
  • Novartis Investigative Site Guangzhou, Guangdong, China
  • Novartis Investigative Site Wuhan, Hubei, China
  • Novartis Investigative Site Nanjing, Jiangsu, China
View Trial Details
Completed

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

NCT00438802

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoblastic Lymphadenopathy, +14 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Holden Comprehensive Cancer Center at University of Iowa Iowa City, Iowa, United States
  • Mayo Clinic Cancer Center Rochester, Minnesota, United States
View Trial Details
Completed

Risk Stratification of Nodal PTCL

NCT03040206

Conditions
Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Chonbuk Nationla University Hospital Jeonju, South Korea
View Trial Details
Completed

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

NCT00932698

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details

Related conditions